Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aclara Biosciences

1995 FOUNDED
PRIVATE STATUS
61-70 EMPLOYEES
IPO LATEST DEAL TYPE
$189M LATEST DEAL AMOUNT
Description

Developer of advanced tools for drug discovery, genomics and proteomics using its proprietary eTagTM assay chemistries and microfluidics expertise. The company's products allow researchers to have decision-critical information for drug development.

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • 1288 Pear Avenue
  • Mountain View, CA 94043
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aclara Biosciences’s full profile, request a free trial.

Aclara Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. IPO 21-Mar-2000 $189M 00000 Completed Generating Revenue
8. Later Stage VC (Series H) 30-Dec-1999 000 000.00 000.00 Completed Generating Revenue
7. Later Stage VC (Series G) 29-Apr-1999 000 000.00 000.00 Completed Generating Revenue
6. Later Stage VC (Series F) 01-Mar-1999 0000 000.00 000.00 Completed Generating Revenue
5. Later Stage VC (Series E) 01-Apr-1998 00.00 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series D) 17-Apr-1997 00000 00.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 01-Nov-1996 00.00 00.00 00.00 Completed Product Development
2. Early Stage VC (Series B) 04-May-1995 $1.4M $3.2M 00.000 Completed Startup
1. Early Stage VC (Series A) 01-May-1995 $1.8M $1.8M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Aclara Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series H 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series G 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series F1 0,000,000 00.000000 00.00 00.0 00.0 00 00.0
Series F 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series E 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series D 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series C 1,076,923 $0.001000 $0.1 $1.3 $1.3 1x $1.3 6.75%
Series B 2,344,466 $0.001000 $0.05 $0.6 $0.6 1x $0.6 14.7%
To view this company’s complete Cap Table, request access »

Aclara Biosciences Executive Team (5)

Name Title Board
Seat
Contact
Info
Bruce Phillips Group President
Bruce Kessler President
Terry Messmer Chief Financial Officer & Vice President
Marty Zucker Executive Vice President, Strategic Initiatives
Randy Bell Vice President, Operations